|
Elena's Biotech Briefing
GT Biopharma is adding AI tools to cancer drug design, Active Motif struck a global genomics distribution deal, and Aureka released an open-source discovery engine.
The top 10 stories from Mon Jul 6, 2026 06:47 AM to Tue Jul 7, 2026 06:48 AM
Generated July 7, 2026 at 6:48 AM
|
|
|
#1 Bayer Foundation Women Entrepreneurs Award: From AI Diagnostics to Circular Food Tech, 15 Women Are Transforming Health and Food Systems Worldwide Published 2026-07-07 On July 7, 2026, the Bayer Foundation Women Entrepreneurs Award selected 15 women from Latin America, Africa, and Asia for work addressing global healthcare and food security. Covered by: prnewswire.com |
#2 A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs Published 2026-07-06 GT Biopharma said it has integrated AI-based tools into discovery and engineering for tumor-targeting NK cell engagers and multi-domain proteins, aiming for efficiency gains to support new development. Covered by: prnewswire.com |
#3 Aureka Releases OpenDDE, an Open-Source Drug Discovery Engine Designed to Accelerate AI-Driven Therapeutic Discovery Published 2026-07-07 Aureka announced the July 6, 2026 release of OpenDDE, an open-source drug discovery engine using an all-atom biomolecular foundation model with co-folding to support scalable therapeutic discovery. Covered by: prnewswire.com |
#4 Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions Published 2026-07-06 Active Motif announced an exclusive global distribution agreement with Arima Genomics to expand Active Motif’s research genomics portfolio and support Arima’s clinical diagnostics focus. Covered by: prnewswire.com |
#5 Biopharma IPO Fundraising And Returns Soar In Q2 Published 2026-07-06 Western exchanges saw biopharma IPO fundraising rise from $1.8 billion in Q1 to $3.8 billion in Q2. Covered by: insights.citeline.com |
#6 Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads Published 2026-07-06 Novartis agreed to acquire London-based Myricx Bio for $1.1 billion upfront and up to $400 million in milestones, with CEO Mohit Rawat citing scientific rationale for NMTi ADC payloads. Covered by: biotechtv.com, biocentury.com |
#7 Inside AbbVie’s Biology-First ADC Strategy Published 2026-07-07 AbbVie is building a large oncology antibody-drug conjugate pipeline and pursuing a strategy focused on matching treatments to patient biology. Covered by: insights.citeline.com |
#8 New sa‑mRNA and LNP Platform to Support Korea’s Hantavirus Vaccine Initiative Published 2026-07-07 Korea University’s Vaccine Innovation Center will lead a government-supported project to develop next-generation hantavirus vaccines using self-amplifying mRNA and LNP platforms. Covered by: genengnews.com |
#9 Genentech Turns To Astex To Shore Up Breast Cancer Pipeline Published 2026-07-06 Astex and Genentech signed a deal to develop breast cancer drugs. Covered by: insights.citeline.com |
#10 Unlocking Microbiome Function with Anaerobic Workflows and Metabolic Phenotyping Published 2026-07-06 The article argues that microbiome research needs anaerobic-preserving workflows and metabolic phenotyping to measure active microbial functions, since sequencing shows presence but not gene expression or real-world activity. Covered by: genengnews.com |
